Extraordinary response of metastatic pancreatic cancer to apatinib after failed chemotherapy: A case report and literature review.
Extraordinary response of metastatic pancreatic cancer to apatinib after failed chemotherapy: A case report and literature review.
复制标题
转移性胰腺癌化疗失败后对阿帕替尼的非凡反应：病例报告和文献综述
DOI：
10.3748/wjg.v23.i41.7478
复制
发表时间：
2017-11-07
影响因子：
4.3
通讯作者：
Wang LL
中科院分区：
文献类型：
--
作者：
Li CM;Liu ZC;Bao YT;Sun XD;Wang LL
化疗对晚期和转移性胰腺癌（PC）的疗效有限，且有严重的副作用。因此，开发新的有效药物，特别是靶向治疗，对PC患者至关重要。我们提出了一个58岁的中国妇女最初诊断为当地先进的PC。随着疾病进展到IV期，患者在四线治疗后无法耐受化疗。然后，她接受阿帕替尼治疗，阿帕替尼是一种新型的高选择性血管内皮生长因子受体-2酪氨酸激酶抑制剂，无进展生存期为7个月。所有药物相关副作用均通过药物治疗得到良好控制。据我们所知，这是第一例对阿帕替尼有反应的PC病例。考虑到这种显著的反应，阿帕替尼可能是治疗PC的有前途的药物。我们还回顾了化疗和靶向治疗的文献，特别是对PC患者的抗血管生成治疗，并研究了阿帕替尼在其他实体瘤中的作用。
Chemotherapy has limited efficacy in the treatment of advanced and metastatic pancreatic cancer (PC), and has serious side effects. The development of novel effective agents, especially targeted therapy, is essential for patients with PC. We present a 58-year-old Chinese woman initially diagnosed with locally advanced PC. As the disease progressed to Stage IV, the patient was unable to tolerate chemotherapy after the fourth-line treatment. She was then treated with apatinib, a novel and highly selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2 and achieved a progression-free-survival of 7 mo. All drug-related side effects were well controlled with medication. To the best of our knowledge, this is the first case of PC which responded to apatinib. Considering this remarkable response, apatinib may be a promising agent in the treatment of PC. We also reviewed the literature on chemotherapy and targeted therapy, especially the anti-angiogenesis therapy for patients with PC, and investigated the effect of apatinib in other solid tumors as well.
登录
查看更多内容
影响因子：
6.2
作者：
Chung, GG;Yoon, HH;Burtness, BA
通讯作者：
Burtness, BA
影响因子：
--
作者：
Assenat E;Azria D;Mollevi C;Guimbaud R;Tubiana-Mathieu N;Smith D;Delord JP;Samalin E;Portales F;Larbouret C;Robert B;Bibeau F;Bleuse JP;Crapez E;Ychou M;Pèlegrin A
通讯作者：
Pèlegrin A
DOI：
10.1084/jem.20111424
发表时间：
2012-03-12
期刊：
The Journal of experimental medicine
影响因子：
--
作者：
Hamerlik P;Lathia JD;Rasmussen R;Wu Q;Bartkova J;Lee M;Moudry P;Bartek J Jr;Fischer W;Lukas J;Rich JN;Bartek J
通讯作者：
Bartek J
影响因子：
6
作者：
Guo, P;Hu, B;Cheng, SY
通讯作者：
Cheng, SY
影响因子：
3.4
作者：
Ko, Andrew H.;Dito, Elizabeth;Tempero, Margaret A.
通讯作者：
Tempero, Margaret A.